Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups
Madhusudhanan Narasimhan, Lenin Mahimainathan, Ellen Araj, Andrew E. Clark, John Markantonis, Allen Green, Jing Xu, Jeffrey A. SoRelle, Charles Alexis, Kimberly Fankhauser, Hiren Parikh, Kathleen Wilkinson, Annika Reczek, Noa Kopplin, Sruthi Yekkaluri, Jyoti Balani, Abey Thomas, Amit G. Singal, Ravi Sarode, Alagarraju Muthukumar
Abstract
The coronavirus disease 19 (COVID-19) pandemic continues to impose a significant burden on global health infrastructure. While identification and containment of new cases remains important, laboratories must now pivot and consider an assessment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity in the setting of the recent availability of multiple COVID-19 vaccines.
Topics & Concepts
VirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BiologyImmunoglobulin M2019-20 coronavirus outbreakImmunologyCoronavirus disease 2019 (COVID-19)Immunoglobulin GMedicineAntibodyOutbreakPathologyInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingCOVID-19 Clinical Research Studies